Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Amgen, Inc. : Amgen : FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 01:22pm CET

Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones.

According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem.

"We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development.

Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million.

A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful.

Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months.

Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; [email protected]

Valeurs citées dans l'article
ChangeLast1st jan.
AMGEN 0.01% 182.45 Delayed Quote.5.22%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN
02/21Merck to buy virus-based cancer drug firm Viralytics for $394 million
RE
02/21AMGEN : AMGN) Stock Price Declined While Profund Advisors LLC Upped by $3.94 Mil..
AQ
02/20AMGEN : Health and Human Services Department (HHS); Food and Drug Administration..
AQ
02/19Rare Haematology Market Trend to 2025 Profiling PRA Health Sciences, Bayer He..
AQ
02/16NOVARTIS : readies to auction U.S. generic pills business - sources
RE
02/15AMGEN : Results From Phase 3 XGEVA® Denosumab Study In Patients With Multiple My..
AQ
02/15AMGEN : Researchers at Amgen Have Reported New Data on Oligopeptides (Rapid scre..
AQ
02/14AMGEN : Announces FDA Advisory Committee Meeting To Review Potential New Use Of ..
PU
02/14+50% CAGR TO BE ACHIEVED BY BIOSIMIL : Global Biosimilars Market – Know In..
AQ
02/14GLOBAL EYE CANCER MARKET REPORT WITH : Global Eye Cancer Market - Global Industr..
AQ
More news
News from SeekingAlpha
02/22IRA Portfolio 1 Year Buying-Selling Update And Now 5.8% Dividend Yield 
02/21UNDERVALUED AND ATTRACTIVE : Pick Up Novartis In 2018 
02/20BIOTECHS : Still Well Placed For More Gains 
02/20AGENUS : Positioned To Rapidly Enhance Shareholder Value 
02/19Healthcare In Transition 
Financials ($)
Sales 2018 22 600 M
EBIT 2018 11 508 M
Net income 2018 8 181 M
Finance 2018 6 263 M
Yield 2018 2,79%
P/E ratio 2018 15,58
P/E ratio 2019 14,36
EV / Sales 2018 5,58x
EV / Sales 2019 5,41x
Capitalization 132 B
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 196 $
Spread / Average Target 7,3%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN5.22%132 428
JOHNSON & JOHNSON-6.33%349 006
NOVARTIS-2.67%224 221
PFIZER-0.58%213 155
ROCHE HOLDING LTD.-9.33%206 183
MERCK AND COMPANY-2.29%148 618